Clinical trials produce the evidence that drives medical progress, but participating involves real risks that potential volunteers should understand before enrolling. Most trial participants have positive experiences, but adverse events do occur, and the risk profile varies significantly by phase, condition, and individual factors. Understanding the actual risks of clinical trials — separating realistic concerns from overblown fears — is essential for informed decision-making. This guide covers the categories of risk, how trials minimize them, what protections exist for participants, and how to evaluate whether a specific trial’s risk-benefit balance is right for you.
Categories of risk in clinical trials
Trial risks fall into several categories:
Physical risks from the experimental treatment: Side effects, adverse reactions, and unforeseen complications from drugs, devices, or procedures being tested. These vary enormously by phase — Phase 1 trials of novel drugs have more uncertainty about safety than Phase 3 trials of drugs with established safety profiles.
Risks from study procedures: Blood draws, biopsies, imaging with contrast, lumbar punctures, and other procedures all carry their own small risks separate from the experimental treatment. Most procedures have very low complication rates but aren’t risk-free.
Risk of receiving placebo: In randomized placebo-controlled trials, participants randomly assigned to placebo don’t receive the experimental treatment. For conditions where standard care exists, this can mean receiving inferior treatment during the trial period.
Time and opportunity costs: The time commitment for trials can be substantial, affecting work, family obligations, and access to other treatments. This isn’t a medical risk but is a real consideration.
Privacy and data risks: Trial participation involves sharing detailed medical information that’s stored and analyzed. Privacy protections exist but are not absolute.
How trial phases affect risk
Risk decreases substantially across phases as more human safety data accumulates:
Phase 1 (highest risk): First testing in humans means safety data is limited. Doses are typically escalated gradually starting from very low levels predicted to be safe based on animal studies. Rare but serious adverse events have occurred — the TGN1412 trial in 2006 resulted in catastrophic immune reactions in all six healthy volunteers, and the BIA 10-2474 trial in 2016 caused brain damage and death in one participant. These events are rare but illustrate that Phase 1 safety isn’t guaranteed.
Phase 2 (moderate risk): The drug has passed Phase 1 safety testing but is being studied in patients with the target condition for the first time. Side effects may emerge that weren’t apparent in healthy volunteers.
Phase 3 (lower risk): Established safety profile from earlier phases. Larger trial size means rarer side effects may be detected. The risk approximates that of taking the drug if it’s approved.
Phase 4 (lowest risk): Drug is already FDA-approved with extensive prior human exposure. Phase 4 risk is similar to taking the approved drug as prescribed, with the added benefit of more intensive monitoring.
What protections exist for participants
Multiple layers of oversight aim to minimize risk:
FDA oversight: The FDA reviews all trial protocols before they begin and can require changes or halt trials if safety concerns emerge. Major pharmaceutical trials are subject to particularly intensive FDA scrutiny.
Institutional Review Boards (IRBs): Independent ethics committees at each trial site review protocols, consent forms, and ongoing safety data. The IRB can require protocol modifications, additional safety monitoring, or trial termination.
Data and Safety Monitoring Boards (DSMBs): For larger trials, independent boards review safety data periodically and can recommend trial termination if safety signals emerge or if the treatment proves clearly superior or inferior to control.
Informed consent: The informed consent process requires that participants understand the risks before enrolling. Consent forms detail known and potential risks and the participant’s right to withdraw at any time.
Adverse event reporting: Trial sponsors are required to report serious adverse events to the FDA and IRBs promptly. Patterns of adverse events trigger protocol modifications or trial termination.
How to evaluate risks for a specific trial
When considering a specific trial, evaluate risks systematically:
- Read the informed consent form carefully — it should detail known and theoretical risks
- Ask the trial coordinator about adverse events that have occurred in this trial or related trials
- Research the drug class — drugs in established classes have known risk patterns
- Consider the phase — Phase 1 carries more uncertainty than Phase 3
- Discuss with your treating physician — they can put trial risks in context with your condition
- Consider what happens if you experience side effects — what’s the protocol for managing them?
Don’t rely solely on the marketing materials. The consent form is the document with the comprehensive risk disclosure.
The placebo problem
Many trials randomize participants to placebo or to the standard of care rather than to the experimental treatment. For conditions where the trial’s experimental treatment may be more effective than current options, receiving placebo means missing out on potential benefit.
Several factors mitigate the placebo concern:
- Most trials of serious conditions don’t use placebo — they compare the new treatment to the current standard of care, so no one is left untreated
- Placebo trials in conditions with no effective treatment options are common and necessary for testing new therapies
- Many trials are open-label extensions where participants can access the experimental treatment after the controlled phase
- Crossover designs let participants receive both placebo and treatment in different phases of the trial
For more on placebo controls, see our placebo-controlled trials guide.
Common adverse events in trials
Most adverse events in trials are mild — headache, nausea, fatigue, injection site reactions, transient lab abnormalities. These typically resolve without treatment or with simple management.
Serious adverse events are less common but occur. Across all clinical trials, the rate of serious adverse events is roughly 1-5% in Phase 3 trials, varying significantly by drug class and condition. Fatal serious adverse events directly attributable to trial drugs are rare — typically under 1 in 1,000 participants in Phase 1-3 trials, though specific drugs in oncology can have higher rates because the underlying disease and the patient population have higher baseline mortality.
Risks for vulnerable populations
Some populations face additional considerations:
Pregnant women: Generally excluded from most trials due to potential fetal effects. Some pregnancy-specific trials exist but with extra protective protocols.
Children: Pediatric trials require additional IRB review and parental consent (with assent from older children). Pediatric drug development is heavily regulated under specific FDA rules.
Elderly patients: Often have multiple comorbidities and complex medication regimens that complicate trial participation. Some trials specifically study elderly populations; others exclude them.
Patients with limited treatment options: Patients with advanced disease or rare conditions sometimes face difficult risk-benefit calculations. Phase 1 oncology trials with patients who have exhausted standard options is the canonical example.
What if something goes wrong
Trial sponsors typically cover medical expenses for serious adverse events directly attributable to the trial drug or procedures. The specifics are detailed in the informed consent and vary by trial. Some trials provide compensation for trial-related injuries; others rely on the participant’s existing insurance.
For routine medical issues unrelated to the trial, your normal insurance applies. The trial doesn’t replace your medical insurance.
Read the consent form carefully for what’s covered. Ask the coordinator specifically what happens if you experience a serious adverse event, who pays, and what compensation may be available.
Frequently Asked Questions
Have people died in clinical trials?
Yes, rarely. Most deaths in clinical trials are from progression of underlying disease (especially in cancer trials) rather than from the experimental treatment. Deaths directly caused by trial drugs are rare but have occurred, particularly in Phase 1 trials of novel mechanisms.
Can I sue if something goes wrong?
Yes, in principle. Participants retain legal rights regardless of consent forms. However, proving that an adverse event was directly caused by the trial drug rather than the underlying condition or other factors can be complex. Consult an attorney for specifics.
Is it safer to be in a trial than to take an approved drug?
Sometimes, paradoxically, yes. Trial participants receive intensive monitoring and rapid response to any concerns. Patients taking approved drugs as standard care may not have the same level of oversight.
What’s the most dangerous phase to participate in?
Phase 1 has the highest uncertainty because drugs have limited prior human exposure. However, individual trials vary enormously — some Phase 1 studies of well-characterized drug classes are quite safe, while some Phase 2-3 trials in vulnerable populations carry substantial risk.
Should I avoid clinical trials?
For most patients with relevant conditions, no. Trial participation provides access to potentially beneficial treatments, intensive monitoring, and contributes to medical progress. The risks should be evaluated for each specific trial rather than dismissed broadly.
The bottom line on clinical trial risks
Clinical trial risks are real but generally manageable for most participants. Phase 1 trials carry the most uncertainty; Phase 4 trials are essentially as safe as taking the approved drug. Multiple oversight layers — FDA, IRBs, DSMBs, and adverse event reporting — exist to minimize and detect problems. Read informed consent forms carefully, discuss with treating physicians, and evaluate each trial individually based on phase, condition, and your personal circumstances. The right trial for you will have a risk-benefit balance that makes sense for your situation, not zero risk.